Synexus has expanded its presence in South Africa with the opening of a new in-patient clinical trials centre in Pretoria.
It is the fourth site in South Africa for the contract research organisation (CRO), and has been developed to cater for phase II and phase III studies that involve 24-hour serial spirometry to test lung function; mixed meal tolerance testing; and pharmacokinetics, that either involves an overnight stay or an infusion.
The site, named Nyeleti, houses both a ward and a dispensing unit, and will support Synexus' existing centres in Pretoria and Mamelodi.
The company's CEO Dr Christophe Berthoux said the decision to expand in South Africa was driven by the country's large, accessible patient pool – many of whom have not had treatment before, which is often a condition of clinical trials.
“There is also a high public awareness of the benefits of clinical trials, which speeds up recruitment and overcomes the lengthy regulatory process,” said Dr Berthoux. “These are all key factors in ensuring the success of a clinical trial.”
South Africa is leading the way in the number of clinical trials conducted in Africa, due to its superior infrastructure as well as a mix of conditions that affect developed and developing nations.
It is currently the only African nation in which Synexus has research facilities where the company has access to more than 3.5m patients and Dr Sanet Aspinall, managing director of Synexus South Africa, said the company was “well positioned” to continue its efforts in the country.
He said: “Access to a core group of well trained and experienced staff at our new in-patient unit and at our dedicated research centres, fast recruitment through our innovative recruitment strategies and the delivery of high quality data will enable us to meet our goals for future growth as a global player in the clinical research industry.”